Co-Diagnostics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CODX in the last 7 days.
No SEC Form 4 filings for $CODX in the last 30 days.
See all $CODX insider activity →Co-Diagnostics (CODX) reported Q2 2026 revenue of $166,131, a slight increase from the previous quarter, with a net loss of $6.3 million, narrowed from $7.7 million. The company highlighted progress in FDA submissions, strategic initiatives, and cost reductions. Management emphasized focus on clinical pipeline and regulatory submissions despite near-term operating losses.
Co-Diagnostics (Nasdaq: CODX) said its Chief Commercialization Officer participated in Salt Lake Business Journal’s 2026 Medical Devices and Innovation Roundtable on Aug. 13. The company also disclosed a 510(k) premarket notification submission to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument, pending FDA clearance.
Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.
Recent CODX coverage spans earnings, technology and corporate actions.
Earnings beat on loss narrowing may support short-term price support; regulatory milestones could drive longer-term upside.
FDA review of the 510(k) submission is the key near-term catalyst for potential clearance and commercialization readiness.
The FDA 510(k) submission and concurrent CLIA waiver application are the key near-term commercialization catalysts, alongside a $3.0M ATM-priced private placement.
Near-term trading focus is the FDA 510(k) submission progress and the cash raise supporting commercialization, alongside continued operating losses.
Regulatory submission progress and associated clinical/analytical data are a near-term catalyst for CODX’s commercialization timeline.
alphai scores every news story that mentions CODX with an AI model for sentiment and relevance, and aggregates insider trades from Co-Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Co-Diagnostics (CODX) reported Q2 2026 revenue of $166,131, a slight increase from the previous quarter, with a net loss of $6.3 million, narrowed from $7.7 million. The company highlighted progress in FDA submissions, strategic initiatives, and cost reductions. Management emphasized focus on clinical pipeline and regulatory submissions despite near-term operating losses.
2 min readCo-Diagnostics (Nasdaq: CODX) said its Chief Commercialization Officer participated in Salt Lake Business Journal’s 2026 Medical Devices and Innovation Roundtable on Aug. 13. The company also disclosed a 510(k) premarket notification submission to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument, pending FDA clearance.
2 min readCo-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.
6 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-
6 min readCo-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.
6 min readCo-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.
2 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Co-Diagnostics, Inc. (the “Company”) entered into an inducement agreement (the “Inducement Letter”) with certain holders (the “Holders”) of certain of the Company’s existing warrants to purchase up to an aggr
4 min readCo-Diagnostics said it completed a proof-of-concept for an extraction-free Ebola test using its Co-Primers technology on the Co-Dx PCR Pro with diluted plasma. The work followed a C-CAMP request for 200 kits. The company is running analytical studies for Bundibugyo kits and developing a second-generation pan-Ebola assay. Shares rose 6.86% to $2.18 premarket.
4 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001692415 0001692415 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readCo-Diagnostics said it has begun clinical studies in India for its PCR Pro TB test platform, following shipments of PCR Pro instruments, MTB test kits, and sample preparation instruments to CoSara. The decentralized PCR platform is designed to return results in about 30 minutes. CoSara is deploying the CoSara-branded instrument in select labs. Co-Diagnostics shares were up 1.69% to $2.40 premarket.
2 min read
